Atlas Trials

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Clinical trial NCT02158936 · TERMINATED

Trial details

NCT number
NCT02158936
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Thrombocytopaenia
Start date
2014-06-10
Primary completion
2016-04-30
Enrollment
356

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.